<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02385604</url>
  </required_header>
  <id_info>
    <org_study_id>12/009/2011</org_study_id>
    <nct_id>NCT02385604</nct_id>
  </id_info>
  <brief_title>The Predictive Value of CT-PET in Esophageal Cancer</brief_title>
  <official_title>CT-PET for Prediction of Histopathologic Response, Nodal Status and Oncologic Outcome Following Neoadjuvant Chemoradiation for Esophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. James's Hospital, Ireland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. James's Hospital, Ireland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A major focus of research in oncology is to identify patients who, following induction
      therapy, have a complete pathologic response, presenting opportunities for novel trials,
      including extended therapy or non-operative approaches, in addition to identifying cohorts
      who are resistant to the neoadjuvant therapy. The current gold standard for determining
      response to CRT is pathological evaluation following surgical resection, in particular the
      Mandard Tumour Regression Grade (TRG) or some modification thereof. At this time, however,
      there is no preclinical early response or post-treatment biomarker, nor endoscopic or
      radiologic assessment that predicts pathologic response prior to surgical resection.The aim
      of this study is to determine the accuracy of CT-PET for prediction of histopathologic
      response and/or oncologic outcome for patients with esophageal cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Undetermined</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>Undetermined</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Histopathologic response</measure>
    <time_frame>Undetermined</time_frame>
    <description>Mandard tumor regression grade, ypT, ypN stage</description>
  </secondary_outcome>
  <enrollment type="Actual">250</enrollment>
  <condition>Esophageal Neoplasms</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Records for all patients with locally advanced esophageal and junctional tumors undergoing
        potentially curative multimodal therapy between November 2008 and November 2014 will be
        assessed.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Locally advanced esophageal or junctional neoplasm

          -  Histologically confirmed adenocarcinoma or squamous cell carcinoma

          -  Scheduled to undergo nCRT followed by surgery as per multidisciplinary Tumor Board

          -  CT-PET at diagnosis of malignancy (within 2 weeks from diagnosis), performed at study
             Center

          -  CT-PET 4-6 weeks after completion of nCRT, prior to surgical resection

        Exclusion Criteria:

          -  Incomplete data, patient lost to follow-up

          -  Scans performed at alternate Center
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John V Reynolds, MCh FRCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Surgery, St. James's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Surgery, St. James's Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>D4</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ireland</country>
  </location_countries>
  <link>
    <url>https://medicine.tcd.ie/surgery/</url>
    <description>Department of Surgery</description>
  </link>
  <reference>
    <citation>Donohoe CL, O'Farrell NJ, Grant T, King S, Clarke L, Muldoon C, Reynolds JV. Classification of pathologic response to neoadjuvant therapy in esophageal and junctional cancer: assessment of existing measures and proposal of a novel 3-point standard. Ann Surg. 2013 Nov;258(5):784-92; discussion 792. doi: 10.1097/SLA.0b013e3182a66588.</citation>
    <PMID>24045450</PMID>
  </reference>
  <reference>
    <citation>Piessen G, Petyt G, Duhamel A, Mirabel X, Huglo D, Mariette C. Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer. Ann Surg. 2013 Jul;258(1):66-76. doi: 10.1097/SLA.0b013e31828676c4.</citation>
    <PMID>23470576</PMID>
  </reference>
  <results_reference>
    <citation>Elliott JA, O'Farrell NJ, King S, Halpenny D, Malik V, Muldoon C, Johnston C, Reynolds JV. Value of CT-PET after neoadjuvant chemoradiation in the prediction of histological tumour regression, nodal status and survival in oesophageal adenocarcinoma. Br J Surg. 2014 Dec;101(13):1702-11. doi: 10.1002/bjs.9670. Epub 2014 Oct 28.</citation>
    <PMID>25351460</PMID>
  </results_reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2015</study_first_submitted>
  <study_first_submitted_qc>March 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2015</study_first_posted>
  <last_update_submitted>March 9, 2016</last_update_submitted>
  <last_update_submitted_qc>March 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. James's Hospital, Ireland</investigator_affiliation>
    <investigator_full_name>Dr Jessie A Elliott</investigator_full_name>
    <investigator_title>Surgical Research Fellow</investigator_title>
  </responsible_party>
  <keyword>Positron-Emission Tomography</keyword>
  <keyword>Neoadjuvant Therapy</keyword>
  <keyword>Chemoradiotherapy</keyword>
  <keyword>Esophagectomy</keyword>
  <keyword>Response Evaluation Criteria in Solid Tumors</keyword>
  <keyword>Treatment Outcome</keyword>
  <keyword>Survival</keyword>
  <keyword>Recurrence</keyword>
  <keyword>Disease-Free Survival</keyword>
  <keyword>Progression-Free Survival</keyword>
  <keyword>Prognosis</keyword>
  <keyword>Neoplasm Grading</keyword>
  <keyword>Adenocarcinoma</keyword>
  <keyword>Squamous Cell Carcinoma</keyword>
  <keyword>Neoplasm Metastasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

